We could prevent diseases so much better but we haven't learned to listen to when biology whispers long (10 years) in advance. A key theme in Super Agers, too. sciencedirect.com/science/ar… @NathanPriceSci @ @nrappapo @BuckInstitute example below for Type 2 diabetes

Good that you posted a response, Peter. Agree, there is no defense for the now public and egregious interactions you had with Epstein. But the man you are today vs 10 years ago has not changed w/r to arrogance. Moreover, these days you are riddled with conflicts as a huckster for David Bars, AG-1 supplement, and so many other things that diminish your credibility. That's a shame.

The menstrual cycle is an overlooked vital sign in mental health.

I hope we as a society are moving the needle on cancer incidence. I remember when we all, and still do, celebrate metformin as an "anti-cancer" drug, associated with 10% cancer reduction in the Look AHEAD trial 👉pubmed.ncbi.nlm.nih.gov/4024… 25-47% reduction in certain cancers sound wildly large. Now we just need to get #GLP1s in the hands of populations #access @EliLillyandCo @novonordiskus jamanetwork.com/journals/jam…

I am thrilled to share our @ACCinTouch Expert Consensus Statement and Concise Clinical Guidance on Medical #WeightManagement ⭐️ jacc.org/doi/10.1016/j.jacc.… Special highlights: 👉GLP1 is just the beginning. Myriads of gut hormone permutations necessitate broader acceptance of the umbrella term: NuSH, nutrient-stimulated hormone 👉We reinforced sex- and ethnic-specific cutoffs for anthropometric measures of excess fat 👉Aligning with #obesity as a chronic disease, the patient’s highest lifetime non-pregnant weight should be considered their diagnostic baseline 👉 Any dose of #NuSH medication can be a maintenance dose, which is supported by our general ethical practice to Do No Harm and to use the lowest therapeutic dose to mitigate risks of side effects Co-written with my esteemed colleagues @DrMarthaGulati @DrOliviaGilbert @tygluckman @MKIttlesonMD @RishiRikhiMD and Joseph Saseen, we aimed to create a guidance for the #cardiology and #obesity communities that is as practical as possible. Clinicians should be able to quote directly from this Statement to appeal to payers and increase #access to high quality care. The obesity space in the US has been desperate for an update to our 2013 AHA/ACC/TOS guidelines. Think of this as a preview!

From one of my upcoming lectures: ~90% of people living with obesity remain untreated.

🚨BREAKING: Lilly’s oral GLP-1, orforglipron, hits its primary endpoint in the Phase 3 ACHIEVE-1 trial for type 2 diabetes. 🔸A1C↓ by 1.3–1.6% 🔸Weight loss: up to 16 lbs (7.9%) 🔸65% hit A1C ≤6.5% Once-daily, oral small molecule GLP-1—no food/water restrictions Safety profile: consistent with injectable GLP-1s ✨ The first oral small molecule GLP-1 to complete Phase 3—game on. #GLP1 #orforglipron #T2D #ObesityCare #ACHIEVE1 prnewswire.com/news-releases…

Lepodisiran Reduced Lp(a) Levels By Upto 95% 1️⃣ Elevated lp(a) levels are strongly associated with increased risk of atherosclerotic cardiovascular disease. 2️⃣ This new study tested lepodisiran—an extended-duration small interfering RNA (siRNA) that targets hepatic production of lp(a)—at doses of 16 mg, 96 mg, and 400 mg, with follow-up for around 180-540 days. 3️⃣ From day 60 to 180, the placebo-adjusted reduction in serum lp(a) levels was −40.8% (16 mg), −75.2% (96 mg), and −93.9% (400 mg). 4️⃣ From day 30 to 360, reductions were −41.2% (16 mg), −77.2% (96 mg), −88.5% (400 mg–placebo), and −94.8% (400 mg–400 mg), showing sustained efficacy over time. 5️⃣ Overall, lepodisiran significantly lowered lp(a) concentrations, with effects lasting well beyond 6 months after a single dose. @NutritionMadeS3 @theproof @DrNadolsky @DrKarlNadolsky @drmatthewnagra @MichaelAlbertMD @maciejbanach @drpablocorral @SABOURETCardio

“In midlife, women experience an average ANNUAL weight increase of 0.7 kg (1.5 lb) and by 2030 it is projected that ~75% of US women will be living with obesity or overweight.”

“It’s more contagious than Covid, more contagious than the flu, more contagious than Ebola,” says Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia.

Eli Lilly to lower price of Zepbound vials, offer more doses Progress. statnews.com/2025/02/25/eli-…

Your ancestry may not impact your candidacy for a job but it definitely matters to your candidacy for preventive medicine #precisionmedicine

Insurance companies don’t pay for healthcare. Employers do. Patients do. Physicians do. Carriers just take a cut, while inflating costs and denying claims. The solution? Cut them out. Physician-led health plans are the future. #healthcare

Captivating insights! This study underscores the importance of not solely relying on Coronary Artery Calcium (CAC) as the marker for low cardiovascular risk. Incorporating Thoracic Aortic Calcium (TAC) measurements could be vital for better risk stratification. This opens up new avenues for predictive diagnostics that go beyond traditional measures. How might this influence your current approach to cardio risk assessments? For anyone looking to dive deeper into the nuances of such studies, visit sciqst.com, a one-stop platform for generating comprehensive biomedical reviews. #Medicine #Cardiology Support Medical Doctors in Uganda: Help by sharing this GoFundMe! 🙏 ❤️ → gofund.me/8be43dd7

After just one night of sleep deprivation, the brain begins to accumulate β-amyloid - a key protein in Alzhiemer’s dementia. 🧵1/10

If the American People Only Knew… Same Surgery, Same Surgeon, Medicare Pays 2x More To Health Systems for No Reason The government claims to care about efficiency. Yet Medicare pays significantly more when a procedure is performed in a health system, owned outpatient department instead of an ASC, even though the care is the same, the outcomes are the same, and the only difference is who profits. @waysandmeans @GOPDoctors @doge

The Physiology of Hunger: @NEJM 🥸 So this is not in CV medicine, but: (1) it is interesting and (2) it has implications for CV 😱 Good job @NEJM - Summary 👇👇👇

The FDA has approved #semaglutide for treating chronic kidney disease #CKD in adults with type 2 diabetes to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death, based on the results of the FLOW trial which demonstrated a 24% reduction in major kidney disease events compared to placebo. novonordisk-us.com/media/new…